This Top Paper Session by Anthony Cleare, United Kingdom, was recorded on 24 September 2024 at the 37th ECNP Congress in Milan, Italy.
Would you like to stay informed about the latest advancements in treatment resistance research? In this presentation, four key papers that were most clinically significant and at the forefront of the field over the past year are highlighted:
- Anand et al. (2023). Ketamine versus ECT for nonpsychotic treatment-resistant major depression. The New England Journal of Medicine.
- Perez et al. (2023). Psilocybin-assisted therapy for depression: A systematic review and dose-response meta-analysis of human studies. European Neuropsychopharmacology.
- Lenze et al. (2023). Antidepressant augmentation versus switch in treatment-resistance geriatric depression. The New England Journal of Medicine.
- Marwaha et al. (2023). Novel and emerging treatments for major depression. Lancet.
Views and opinions expressed in these videos are those of the presenters and do not necessarily reflect the official position of ECNP. The content of these videos should not be used in any way as the basis for treatment decisions.
